Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490253 | 1.00 | ELANE (0.66) | ELANE | |
| SCHEMBL31490192 | 0.89 | ELANE (0.70) | ELANE | |
| SCHEMBL561449 | 0.89 | ELANE (0.70) | ELANE | |
| SCHEMBL31490262 | 0.87 | ELANE (0.67) | ELANE | |
| SCHEMBL561912 | 0.87 | ELANE (0.67) | ELANE | |
| SCHEMBL560794 | 0.86 | ELANE (0.72) | ELANE | |
| SCHEMBL31490414 | 0.85 | ELANE (0.65) | ELANE | |
| SCHEMBL31490333 | 0.85 | ELANE (0.65) | ELANE | |
| SCHEMBL561091 | 0.85 | ELANE (0.65) | ELANE | |
| SCHEMBL561631 | 0.85 | ELANE (0.65) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | claimed |
| WO-2015114144-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NETHERTON SYNDROME | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-08-06 | — | — | WO | disclosed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.